IMUGENE CHART. TA only, page-13117

great post.
to recap , with HER-Vaxx,

16/11/21 Ann. Neo HERIZON, Merck KGaA and Pfizer. Comparison of HER Vaxx and chemo, with or without avelumab( anti PD L1 checkpoint inhibitor)

13/12 21 Ann. Next HERIZON .FDA approval of IND to commence study with pembrolizumab( KEYTRUDA)
note ,

15/03/22 agreement with Merck , to supply Keytruda. Details of trial, HER-Vaxx plus chemo vs HER Vaxx plus Keytuda, in pts that have failed trastuzumab

So, since 13/12/21, Merck has agreed to collaborate, and supply Keytruda free of charge. Wonder why, the delay. ? . .??.waiting for further info on OS, in the ongoing HERIZON trial. ( I would love to see the OS result analysis released soon)
Im not suprised the announcement was price sensitive.
Im not suprised the “ market “ doesn’t reflect yet that is a good announcement

as this reply is on a chart thread, I’ll show EMA 3 , crossing with EMA 9 .
a little unusual I’ll admit, but seems to work.
We seem to be crossing again, have had a few tries in this downtrend, maybe good luck this time.
( message to self, wish I’d traded 1/3 of my holding on this chart, selling at 0.56, and buying back now)



work . ( was shown the “ rule of 3’s “ many years ago by Prof RH, in a different area)